Study On The Bioequivalence In Human Body And The Analysis Of Clinical Use Of Ribavirin Tables

Backgrounds: Hepatitis C is a global pandemic. It was reported by World Health Organization (WHO) that the global infection rate of hepatitis C virus (HCV) was about 3 percent and the infected people was estimated at more than 0.17 billion. Ribavirin oral dosage forms are one of the important known therapeutic drugs. The ribavirin tablets prepared by Shandong Qidu Pharmaceutical Co. Ltd. is the new-drug of chemical drugs class VI. The study of the drug's bioequivalence is the basis of new drug approval and its clinical application. The clinical use of the Ribavirin combined with PEG-interferon (PEG-INF) in treating hepatitis C was analyzed to provide references for the rational use of the drugs. Objectives: The bioequivalence of ribavirin tested preparation and reference preparation was studied in this paper, which would provide evidences for new drug approval and clinical use.The clinical curative effect of the combined ribavirin and PEG-INF to treat hepatitis C was evaluated and analyzed, which would promote the rational use of the drugs.Methods: The concentration of ribavirin in blood was determined by HPLC method after single oral doses of tested preparation and...